{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:48:30Z","timestamp":1787024910242,"version":"build-2736575974"},"reference-count":52,"publisher":"Informa UK Limited","issue":"sup15","funder":[{"name":"Roche, CELLTRION and Janssen"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.2217\/fon-2017-0153","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T04:34:23Z","timestamp":1494304463000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":37,"title":["An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements"],"prefix":"10.1080","volume":"13","author":[{"given":"Christian","family":"Buske","sequence":"first","affiliation":[{"name":"CCC Ulm,University Hospital Ulm,\rUlm,\rGermany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology,Tokai Central Hospital,\rGifu,\rKakamigahara,\rJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyuk-Chan","family":"Kwon","sequence":"additional","affiliation":[{"name":"CELLTRION Healthcare Co. Ltd,\rIncheon,\rRepublic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wook","family":"Yoon","sequence":"additional","affiliation":[{"name":"CELLTRION Healthcare Co. Ltd,\rIncheon,\rRepublic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1090051"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/11201110-000000000-00000"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3236"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2196"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3276"},{"key":"e_1_3_3_8_1","unstructured":"Schellens J\n. Controversy of the day. Biosimilars and bioequivalents: a wise choice in a demanding treatment landscape? ESMO 2016 Daily Reporter. www.esmo.org\/Conferences\/ESMO-2016-Congress\/News-Articles\/Controversy-of-the-Day-Biosimilars-and-bioequivalents-A-wise-choice-in-a-demanding-treatment-landscape\/"},{"key":"e_1_3_3_9_1","unstructured":"Fromer M\n. Understanding biosimilars and their impending role in oncology care. ASCO Post. www.ascopost.com\/issues\/november-25-2016\/understanding-biosimilars-and-their-impending-role-in-oncology-care\/"},{"key":"e_1_3_3_10_1","unstructured":"European Medicines Agency\n. European public assessment report for Truxima. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004112\/WC500222696.pdf"},{"key":"e_1_3_3_11_1","unstructured":"European Medicines Agency\n. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf"},{"key":"e_1_3_3_12_1","unstructured":"U.S. Food & Drug Administration\n. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000142"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.258"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30374-6"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.04.003"},{"key":"e_1_3_3_17_1","unstructured":"European Medicines Agency\n. Procedural advice for users of the centralised procedure for generic\/hybrid applications. www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/10\/WC500004018.pdf"},{"key":"e_1_3_3_18_1","unstructured":"European Medicines Agency\n. Guideline on the investigation of bioequivalence. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-016-0028-9"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1040973"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3444-0"},{"key":"e_1_3_3_22_1","unstructured":"Generics and Biosimilars Initiative\n. Biosimilars approved in Europe. www.gabionline.net\/Biosimilars\/General\/Biosimilars-approved-in-Europe"},{"key":"e_1_3_3_23_1","unstructured":"Amgen Ltd\n. Neupogen Summary of Product Characteristics. Neupogen 30 MU (0.3 mg\/ml) solution for injection. www.medicines.org.uk\/emc\/medicine\/27485"},{"key":"e_1_3_3_24_1","unstructured":"Janssen-Cilag Ltd\n. Eprex Summary of Product Characteristics. Eprex 10.000 IU\/ml solution for injection in pre-filled syringe. www.medicines.org.uk\/emc\/medicine\/29446"},{"key":"e_1_3_3_25_1","unstructured":"Sandoz Inc\n. Zarxio Prescribing Information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125553lbl.pdf"},{"key":"e_1_3_3_26_1","unstructured":"CELLTRION Inc\n. Inflectra Prescribing Information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125544s000lbl.pdf"},{"key":"e_1_3_3_27_1","unstructured":"CELLTRION Inc\n. Remsima Summary of Product Characteristics. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002576\/WC500150871.pdf"},{"key":"e_1_3_3_28_1","unstructured":"U.S. Food & Drug Administration\n. List of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/Biosimilars\/UCM439049.pdf"},{"key":"e_1_3_3_29_1","unstructured":"American Cancer Society\n. LIVESTRONG. The global economic cost of cancer. https:\/\/old.cancer.org\/acs\/groups\/content\/@internationalaffairs\/documents\/document\/acspc-026203.pdf"},{"key":"e_1_3_3_30_1","unstructured":"World Health Organization\n. Early cancer diagnosis saves lives cuts treatment costs. www.who.int\/mediacentre\/news\/releases\/2017\/early-cancer-costs\/en\/"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0196-3"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"e_1_3_3_33_1","unstructured":"I.M.S. Health\n. Global market for cancer treatments grows to $107 billion in 2015 fuelled by record level of innovation. www.imshealth.com\/en\/about-us\/news\/ims-health-study-global-market-for-cancer-treatments-grows-to-107-billion-in-2015-fueled-by-record-level-of-innovation"},{"key":"e_1_3_3_34_1","unstructured":"I.M.S. Institute for Healthcare Informatics\n. Medicines use and spending in the U.S. A review of 2015 and outlook to 2020. https:\/\/morningconsult.com\/wp-content\/uploads\/2016\/04\/IMS-Institute-US-Drug-Spending-2015.pdf"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0207-0"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1008346"},{"issue":"6","key":"e_1_3_3_37_1","first-page":"1010","article-title":"Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM)","volume":"96","author":"Gori S","year":"2010","unstructured":"Gori S , Di MaioM, PintoCet al. Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM). Tumori96(6), 1010\u20131015 (2010).","journal-title":"Tumori"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70365-1"},{"key":"e_1_3_3_39_1","unstructured":"I.M.S. Institute for Healthcare Informatics\n. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. www.imshealth.com\/files\/web\/IMSH%20Institute\/Healthcare%20Briefs\/Documents\/IMS_Institute_Biosimilar_Brief_March_2016.pdf"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-014-0595-3"},{"key":"e_1_3_3_41_1","volume-title":"12th Congress of the European Crohn's and Colitis Organisation.","author":"Han S","year":"2017","unstructured":"Han S , KimS, KimJet al. The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016. Presented at: 12th Congress of the European Crohn's and Colitis Organisation.Barcelona, Spain, 15\u201318 February 2017 (Abstract P582)."},{"key":"e_1_3_3_42_1","unstructured":"European Medicines Agency\n. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/06\/WC500167838.pdf"},{"key":"e_1_3_3_43_1","unstructured":"European Medicines Agency\n. Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non-clinical and clinical issues. www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf"},{"key":"e_1_3_3_44_1","unstructured":"U.S. Food & Drug Administration\n. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. www.fda.gov\/downloads\/drugs\/guidances\/ucm291134.pdf"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209540"},{"key":"e_1_3_3_47_1","unstructured":"Clinical Trials Database: NCT01534884. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01534884"},{"key":"e_1_3_3_48_1","unstructured":"Clinical Trials Database: NCT02149121. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02149121"},{"issue":"10","key":"e_1_3_3_49_1","first-page":"Abstract 1634","article-title":"Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks","volume":"68","author":"Suh C-H","year":"2016","unstructured":"Suh C-H , KasayA, El-KhouriEet al. Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks. Arthritis Rheumatol.68(Suppl. 10), Abstract 1634 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1807.1807"},{"key":"e_1_3_3_51_1","unstructured":"Clinical Trials Database: NCT02162771. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02162771"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.5111.5111"},{"issue":"10","key":"e_1_3_3_53_1","first-page":"Abstract 1635","article-title":"Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks","volume":"68","author":"Yoo D-H","year":"2016","unstructured":"Yoo D-H , MajstorovicL, KasayAet al. Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks. Arthritis Rheumatol.68(Suppl. 10), Abstract 1635 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2016.03.006"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:44:43Z","timestamp":1719110683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":52,"journal-issue":{"issue":"sup15","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.2217\/fon-2017-0153"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0153","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}